Synbiotics Reduce Hypercholesterolemia and Aortic Inflammation Via Modulation of Cholesterol Metabolism
Synbiotics have emerged as a potential intervention to alleviate high-fat diet (HFD)-induced metabolic and cardiovascular dysfunction. Here, we evaluated a novel synbiotic formulation in HFD-fed ApoE⁻/⁻ mice for its effects on lipid metabolism, intestinal and systemic T-cell immunity, and gut microbiome composition. ApoE⁻/⁻ mice were fed a HFD and treated with either vehicle or synbiotics for 4 weeks. Serum LDL cholesterol levels and hepatic lipid accumulation and cholesterol content were assessed. Expression of cholesterol metabolism genes was analyzed in the liver and in the small intestine. Flow cytometry was used to examine T-cell populations in mesenteric lymph nodes and spleen. Gut microbiome composition was profiled by shotgun sequencing, and short-chain fatty acid (SCFA) levels were quantified in serum and stool as well as aortic inflammation was evaluated. Synbiotic treatment significantly reduced LDL cholesterol and hepatic lipid accumulation without altering body or organ weights. In the intestine, synbiotics attenuated HFD-induced dysregulation of cholesterol metabolism genes and maintained hepatic cholesterol levels comparable to standard chow-fed mice. Immunologically, synbiotic-fed mice showed reduced Th17 cells in mesenteric lymph nodes and increased cytotoxic T cells in the spleen, indicating immune reprogramming. Despite HFD-induced dysbiosis, synbiotic treatment preserved SCFA-producing taxa, including Lactobacillus johnsonii , Bacteroides fragilis , and Eubacterium spp., and significantly increased fecal butyrate levels. Notably, synbiotic-treated mice showed a complete absence of aortic inflammation, in contrast to vehicle-treated HFD controls. In conclusion, synbiotic intervention ameliorates diet-induced cardiometabolic dysfunction in HFD-fed ApoE⁻/⁻ mice by modulating intestinal cholesterol metabolism, restoring microbiota-derived metabolite production, and reshaping T-cell responses. These findings support synbiotics as a promising strategy to counter diet-driven cardiometabolic dysfunction.
Authors
- Meena Kumari Palani Kumar (ORCID: https://orcid.org/0000-0003-4305-1222)
- Theda Ulrike Patricia Bartolomaeus (ORCID: https://orcid.org/0000-0002-5156-7184)
- Nicola Wilck (ORCID: https://orcid.org/0000-0003-3189-5364)
- Prakash Motiram Halami (ORCID: https://orcid.org/0000-0002-0293-1891)
- Arash Haghikia (ORCID: https://orcid.org/0000-0002-5646-3237)
- Sabrina Geisberger (ORCID: https://orcid.org/0000-0001-6477-1312)
- Lajos Markó (ORCID: https://orcid.org/0000-0003-1888-5575)
- Łukasz Przybył (ORCID: https://orcid.org/0000-0001-9777-8879)
- Stefan Kempa (ORCID: https://orcid.org/0000-0002-0696-9299)
- Ulrike Löber (ORCID: https://orcid.org/0000-0001-7468-9531)
- Ariana Rauch (ORCID: https://orcid.org/0000-0002-5152-5830)
- Anna Karlik (ORCID: https://orcid.org/0009-0009-1610-1045)
- Wibke Anders (ORCID: https://orcid.org/0009-0000-6069-4233)
- Muthukumar Serva Peddha
- Sofia K Forslund
- Dorota Szmigiel
Institutions
- Central Food Technological Research Institute (IN)
- Max Delbrück Center (DE)
- Humboldt-Universität zu Berlin (DE)
- Deutsches Herzzentrum der Charité (DE)
- German Centre for Cardiovascular Research (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Institute of Bioorganic Chemistry, Polish Academy of Sciences (PL)
- Franklin University (US)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Academy of Scientific and Innovative Research (IN)
Publication Details
- Journal
- Probiotics and Antimicrobial Proteins
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1007/s12602-026-11313-2
- Primary Topic
- Gut microbiota and health
- Type
- article
- Field-Weighted Citation Impact
- 0.00